[HTML][HTML] Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs
LE Markowitz, M Drolet, RM Lewis, P Lemieux-Mellouki… - Vaccine, 2022 - Elsevier
Background Human papillomavirus (HPV) vaccines were first licensed as a three-dose
series. Two doses are now widely recommended in some age groups; there are data …
series. Two doses are now widely recommended in some age groups; there are data …
Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage
JML Brotherton, PN Bloem - Best practice & research Clinical obstetrics & …, 2018 - Elsevier
Persistent oncogenic human papillomavirus (HPV) is the cause of cervical cancer, as well as
cancers of the anus, penis, vulva, vagina and oropharynx. There is good evidence that …
cancers of the anus, penis, vulva, vagina and oropharynx. There is good evidence that …
[HTML][HTML] Human papillomavirus vaccine effectiveness by number of doses: systematic review of data from national immunization programs
Background Human papillomavirus (HPV) vaccines were first licensed as a three-dose
series; a two-dose series is now recommended in some age groups and there is interest in …
series; a two-dose series is now recommended in some age groups and there is interest in …
Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence
DR Brown, EA Joura, GP Yen, S Kothari… - Vaccine, 2021 - Elsevier
Background The extent of cross-protection provided by currently licensed bivalent and
quadrivalent HPV vaccines versus direct protection against HPV 31-, 33-, 45-, 52-, and 58 …
quadrivalent HPV vaccines versus direct protection against HPV 31-, 33-, 45-, 52-, and 58 …
Human papillomavirus vaccine effectiveness against HPV infection: evaluation of one, two, and three doses
LE Markowitz, AL Naleway, NP Klein… - The Journal of …, 2020 - academic.oup.com
Background Highly effective human papillomavirus (HPV) vaccines are used in many
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …
Comparison of the long‐term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study
AM Rodriguez, B Zeybek, M Vaughn, J Westra, S Kaul… - Cancer, 2020 - Wiley Online Library
Background Human papillomavirus (HPV)–related disease remains a significant source of
morbidity and mortality, and this underscores the need to increase HPV vaccination to …
morbidity and mortality, and this underscores the need to increase HPV vaccination to …
[HTML][HTML] Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2, 2 million individuals
Abstract Background In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination
for girls at 12–13 years of age to protect against virus types causing cervical cancer …
for girls at 12–13 years of age to protect against virus types causing cervical cancer …
Data resource profile: the Valencia health system integrated database (VID)
A García-Sempere, A Orrico-Sánchez… - International Journal …, 2020 - academic.oup.com
Advance Access Publication Date: 16 January 2020 Data Resource Profile geographically
organized into Primary Healthcare Districts (around 5000–25 000 people served by one …
organized into Primary Healthcare Districts (around 5000–25 000 people served by one …
Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination
G Tyros, S Mastraftsi, S Gregoriou… - … journal of STD & …, 2021 - journals.sagepub.com
Anogenital warts (AGWs) rank among the most frequent sexually transmitted infections in
young adults. They are benign lesions, but they pose a significant economic cost to health …
young adults. They are benign lesions, but they pose a significant economic cost to health …
Review of vaccination recommendations in guidelines for non-communicable diseases with highest global disease burden among adults 75 years old and above
AR Ishak, YC Hsieh, H Srinivasan, KC See - Vaccines, 2023 - mdpi.com
This scientific review paper explores international and country-specific healthcare
guidelines for non-communicable diseases with the highest burden among individuals aged …
guidelines for non-communicable diseases with the highest burden among individuals aged …